Cancer Drugs Show Promise for Alzheimer's

Scientists have identified two existing cancer drugs, letrozole and irinotecan, as promising candidates for treating Alzheimer's disease.

These FDA-approved medications were found to reverse changes in gene expression linked to Alzheimer's. Initial research focused on computational tools to analyze gene expression alterations in the brain.

Testing in mouse models demonstrated that the drug combination significantly reduced tau protein clumps. The mice also showed notable improvements in learning and memory capabilities.

Letrozole targeted neurons, while irinotecan acted on glia, suggesting a multi-faceted approach. This research could pave the way for more personalized Alzheimer's treatments in the future.

Future clinical trials are anticipated, though potential side effects of the repurposed drugs must be carefully considered. The global prevalence of Alzheimer's highlights the urgency for effective interventions.